NUCLEOLIN and cancer: Taken together, our studies suggest that inducing antigens in tumor cells in situ by nucleolin-targeted downregulation of TAP could be as if not more effective than vaccinating against endogenous neoantigens, clinically more feasible, and broadly applicable to all cancer patients.